If FCR is the procedure of alternative, caution needs to be taken in individuals with NOTCH1 mutations, in whom rituximab seems to own minor added value.59 Other genomic subgroups, for instance people with BIRC3 mutations seem to derive tiny benefit from CIT,111,112 but these benefits should be even more validated. https://eddief789vsn6.blogginaway.com/profile